Newsroom
For media inquiries, please contact 340B Health Senior Vice President of Communications Jon Tilton at jon.tilton@340bhealth.org or 202-536-2285.
-
STATEMENT ON 22ND DRUG COMPANY REFUSING TO OFFER 340B DRUG PRICING; NOVO NORDISK FURTHER RESTRICTS 340B CONTRACT PHARMACY PRICING
-
STATEMENT ON COMMITTEE PASSAGE OF HARMFUL HOUSE 340B LEGISLATION
-
JOINT STATEMENT FROM NATIONAL HOSPITAL AND PHARMACIST ASSOCIATIONS ON HARMFUL HOUSE 340B LEGISLATION
-
STATEMENT ON HOUSE SUBCOMMITTEE APPROVAL OF 340B REPORTING MANDATE
-
AHA, 340B HEALTH, ARKANSAS HOSPITAL ASSOCIATION URGE FEDERAL APPEALS COURT TO UPHOLD STATE LAW PROTECTING 340B COMMUNITY PHARMACIES
-
340B HEALTH ADDS VETERAN COMMUNICATIONS LEADER TO TEAM
-
STATEMENT ON THE BIPARTISAN PROTECT 340B ACT TO BAN DISCRIMINATORY PAYMENT POLICIES
-
REPORT: DRUG COMPANIES STRIPPING BILLIONS OF DOLLARS FROM HEALTH CARE SAFETY NET TO AVOID 340B PENALTIES AND SPECIALTY DRUG DISCOUNTS
-
JOINT STATEMENT FROM NATIONAL HOSPITAL AND PHARMACIST ASSOCIATIONS ON PHRMA-LED PROPOSAL TO RESTRICT 340B ELIGIBILITY
-
STATEMENT ON PHRMA AND NACHC PROPOSAL TO REDUCE SAFETY-NET HOSPITAL PARTICIPATION IN 340B
-
STATEMENT ON NEW JOHNSON & JOHNSON RESTRICTIONS ON 340B ACCESS
-
UPDATED: STATEMENT ON BAYER AND EMD SERONO RESTRICTING 340B DISCOUNTS THROUGH COMMUNITY-BASED PHARMACIES